HCG Oral Tablets are not a legal or widely recognized form of medication. Currently, HCG is mainly used in injectable form (such as powder injections or solutions) for medical purposes. Oral tablets may involve illegal products or unverified supplements, posing safety risks and lacking scientific evidence to support their effectiveness. HCG may face the problem of low bioavailability in oral form, where the drug is broken down or poorly absorbed in the gastrointestinal tract, resulting in the inability to achieve effective blood drug concentrations. Simultaneously using illegal or unverified HCG oral products may lead to serious health risks, including but not limited to allergic reactions, cardiovascular problems, endocrine disorders, etc. Due to the low bioavailability of oral HCG, users may need to take higher doses to achieve the expected effects, further increasing health risks.
We not only provide pure powder and capsules, but also other dosage forms. If necessary, please contact our sales team.
Our products
|
|
|
|
| HCG Injection 5000iu | HCG Diet Capsules | HCG Oral Tablets |
|
|
|
| HCG Powder | Best HCG Drops |
HCG COA
Challenges and current research progress of oral HCG preparations
Core obstacles to oral bioavailability
HCG Oral Tablets, as a macromolecular protein, faces two major barriers for oral absorption:
Gastrointestinal degradation: Digestive enzymes such as pepsin and trypsin can hydrolyze the peptide bonds of HCG, disrupting its tertiary structure.
First pass effect: After intestinal absorption, HCG needs to enter the liver through the portal vein system and be further metabolized and inactivated.
Existing research shows that the oral bioavailability of unmodified HCG is close to zero. For example, in an animal experiment, after oral administration of HCG to rats, no significant increase in serum β - HCG levels was detected, while the serum concentration of the injection group increased in a dose-dependent manner.
Development strategy of oral preparations
To overcome the aforementioned obstacles, researchers attempt the following technical approaches:
Chemical modification and structural protection
Polyethylene glycol (PEG) modification increases the molecular weight of HCG by covalently linking PEG molecules (such as PEG-40 stearate modification), reduces renal excretion, and lowers immunogenicity. A patent (CN103826640A) proposes to combine 17 hydroxyprogesterone (17HP) with PEG derivatives (such as PEG-20 oleate) to form an oral delivery system, but does not directly involve HCG. Encapsulate HCG in a lipid bilayer and utilize the lipophilicity of liposomes to promote intestinal absorption. For example, a study used long-chain triglycerides (LCT) and surfactants (such as Poloxamer 188) to prepare HCG liposomes, which increased the uptake of small intestinal epithelial cells by three times after oral administration. Nanoparticle technology is the preparation of HCG nanoparticles (particle size<200 nm) through nanoprecipitation or self-assembly techniques, utilizing the phagocytic activity of intestinal epithelial cells to enhance absorption. Experiments have shown that the oral bioavailability of nanoparticle formulations can reach 5% -10% of that of injections.
Application of absorption enhancers
Bile salts, such as sodium deoxycholate (SDC), increase paracellular absorption by disrupting the tight junctions between intestinal epithelial cells. In a clinical trial, HCG oral tablets supplemented with 0.5% SDC increased serum β-HCG levels to eight times that of the control group.
Surfactants, such as polysorbate 80 (Tween 80), promote the dissolution and absorption of HCG by reducing interfacial tension. Animal experiments have shown that Tween 80 can increase the oral absorption rate of HCG from 0.2% to 1.5%.
Enzyme inhibitors, such as aprotinin, reduce HCG degradation by inhibiting trypsin activity. In vitro experiments have shown that aprotinin can extend the stability of HCG in simulated intestinal fluid from 15 minutes to 2 hours.
Prodrug design and targeted delivery
Prodrug strategy: Connect the active site of HCG (such as β subunit) to a protective group through a hydrolyzable bond, and release the active HCG in the alkaline environment of the small intestine after oral administration. For example, a study covalently bound lysine residues of HCG with acetyl groups, and after oral administration, released active HCG under the action of intestinal esterase, with a bioavailability of 3%.
Targeted modification: By connecting to carriers such as vitamin B12 (VB12) or transferrin (Tf), specific receptors on the surface of intestinal epithelial cells (such as VB12 receptors and Tf receptors) are used to mediate endocytosis. The experiment showed that the oral absorption of VB12-HCG conjugate was 12 times that of unmodified HCG.
Specific manufacturing process of HCG oral tablets
Preparation of raw materials and reagents
HCG raw materials: recombinant HCG (r-HCG) or urine extracted HCG (u-HCG), purity ≥ 95% (HPLC detection).
The excipients are absorption enhancers: Sodium Deoxycholate (SDC, 0.5% -2% w/w), Polysorbate 80 (Tween 80, 1% -5% w/w).
Enzyme inhibitor: Aprotinin (0.1% -0.5% w/w).
Fillers: Microcrystalline cellulose (MCC, 30% -50% w/w), lactose (20% -40% w/w).
Adhesive: polyvinylpyrrolidone (PVP K30, 2% -5% w/w), hydroxypropyl methylcellulose (HPMC, 1% -3% w/w).
Lubricants: Magnesium stearate (MgSt, 0.5% -1% w/w), Silicon dioxide (0.5% -1% w/w).
Solvent: Deionized water, ethanol (95%).
Process Flow
HCG pretreatment
Dissolve: Dissolve HCG raw material (100 mg) in 10 mL of phosphate buffer solution (PBS, pH 7.4), add aprotinin (1 mg) and SDC (200 mg), and stir until completely dissolved.
Freeze drying: Transfer the solution to a freeze drying bottle, pre freeze at -80 ℃ for 2 hours, and then place it in a freeze dryer (vacuum degree<0.1 mbar, cold trap temperature -50 ℃) for 48 hours to obtain HCG-SDC composite powder.
Granulation and compression
Wet granulation: Mix HCG-SDC complex powder (100 mg), MCC (500 mg), and lactose (300 mg) evenly. Add PVP K30 solution (5% w/v, 10 mL) as a binder and stir rapidly until uniform wet particles are formed. Filter the whole granule through a 20 mesh sieve and dry it at 60 ℃ for 2 hours.
Dry granulation (optional): Mix HCG-SDC composite powder MCC, After mixing lactose, it is pressed into thin sheets by a roller press, and then crushed and sieved to obtain particles.
Tablet pressing: Mix dry granules with magnesium stearate (10 mg) evenly. Press into tablets with a diameter of 8 mm and a weight of 500 mg using a single stamping press (pressure 10-15 kN).
Coating (optional)
Purpose: To mask unpleasant odors, control drug release, and improve stability.
workmanship
Preparation of coating solution: Dissolve HPMC (5% w/v) and polyethylene glycol 400 (PEG 400, 2% w/v) in ethanol (95%).
Place the tablets in a coating pot and spray the coating solution until the tablets gain 5% -10% weight.
Dry at 40 ℃ for 1 hour to obtain coated tablets.
Quality control
Tablets should be intact, smooth, without any cracks or spots.
Take 20 pieces, accurately weigh the total weight, calculate the average piece weight, and the weight difference of each piece should be within ± 5%.
Using a hardness tester, the tablet hardness should be ≥ 50 N.
HPLC method: Using a C18 column (4.6 mm × 250 mm, 5 μ m) as the stationary phase, acetonitrile water (30:70, containing 0.1% TFA) as the mobile phase, flow rate of 1.0 mL/min, detection wavelength of 220 nm. The HCG peak area should be compared with the standard curve to calculate the content, which should be between 90% and 110% of the labeled amount.
ELISA method: Use HCG specific antibodies to coat the enzyme-linked immunosorbent assay (ELISA) plate, add the extract of the test tablet, and determine the HCG content through competitive binding reaction.
Key points of preclinical research on HCG oral tablets
Pharmacokinetic (PK) study
Model selection for animal experiments: rats or beagle dogs, blood samples are collected at regular intervals (0, 0.5, 1, 2, 4, 8, 12, 24 hours) after oral administration.
Detection indicators: serum β - HCG concentration (ELISA method), peak time (Tmax), peak concentration (Cmax), and area under the drug time curve (AUC).
Result analysis: Compared with injections, calculate the oral bioavailability (F=AUC oral/AUC injection x 100%).
In vitro simulation experiment - Aco-2 cell model: evaluating the transport efficiency of HCG tablets in intestinal epithelial cells.
Artificial gastric/intestinal fluid stability: detecting the degradation of HCG in a simulated digestive environment.
Pharmacodynamic (PD) studies
The animal model is a cryptorchidism model: young rats were orally administered HCG tablets to observe testicular descent rate and histological changes.
Hypogonadism model: Oral administration of HCG to castrated rats, detection of serum testosterone levels and changes in epididymal weight.
Mechanism study: Western blot was used to detect the expression of StAR protein (acute regulator of steroid synthesis protein) in testicular interstitial cells, to verify the promoting effect of HCG on testosterone synthesis.
Safety evaluation
Acute toxicity experiment: After a single oral administration of the maximum dose (such as 500 mg/kg), observe animal behavior, body weight, organ coefficients (heart, liver, spleen, lungs, kidneys), and histopathological changes.
Long term toxicity test: Continuous oral administration for 28 days, testing blood routine, blood biochemistry (ALT, AST, BUN, Cr), electrolytes (Na ⁺, K ⁺, Cl ⁻), and pathological changes in major organs.
Genetic toxicity experiments: Ames test, mouse micronucleus test, chromosome aberration test, to evaluate the mutagenicity of HCG.
Hot Tags: hcg oral tablets, China hcg oral tablets manufacturers, suppliers, CJC 1295 Injection, CJC 1295 NO DAC 2mg, HCG Injection 5000iu, IGF 1 LR3 Capsule, IGF 1 LR3 Lyophilized, IGF 1 LR3 Spray
